logo
logo

Cullinan Oncology Completes $98.5 Million Series B Financing

Jun 04, 2020•about 5 years ago

Amount Raised

$98 Million

Round Type

series b

CambridgeHealthcare

Description

Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio. New institutional investors and family offices participated in the financing alongside original commitments from founding investors MPM Capital and F2 Ventures. Following the completion of the fundraising, Tim Anderson of Cowen Healthcare investments (CHI) has joined the Board.

Company Information

Company

Cullinan Oncology

Location

Cambridge, Maryland, United States

About

Cullinan’s business model is predicated on distributing risk while maximizing optionality inherent in novel science through the construction of a diversified portfolio of internally developed as well as externally sourced oncology assets. Cullinan’s scalable model minimizes the fixed costs and inefficiencies of many traditional development approaches through strategic partnerships and a shared services platform. For more information, visit www.cullinanoncology.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People